Retatrutide Phase 3 TRIUMPH-4 data (December 2025): 28.7% mean weight loss at 68 weeks with 12 mg
4 Well continue to post updates as they occur
Therefore, direct protection of cardiovascular system and favorable effects on multiple cardiovascular risk factors (hyperglycemia, blood pressure, dyslipidemia, body weight) observed in patients receiving GLP-1RAs may provide an explanation for the cardiovascular benefits of GLP-1RAs (Fig
Patients can expect to lose a significant percentage of their body weight when combined with lifestyle changes
References Jaeschke H, Murray FJ, Monnot AD, Jacobson-Kram D, Cohen SM, Hardisty JF, Atillasoy E, Hermanowski-Vosatka A, Kuffner E, Wikoff D, Chappell GA, Bandara SB, Deore M, Pitchaiyan SK, Eichenbaum G (2021) Assessment of the biochemical pathways for acetaminophen toxicity: implications for its carcinogenic hazard potential
For cancer patients, your PMC provider coordinates with your oncologist